Figure 1.

Increased frequencies of gMDSC in patients with ALD. A, Representative gating strategy for gMDSCs from freshly isolated peripheral blood mononuclear cells of healthy controls (HC), alcoholic hepatitis (AH) and alcoholic liver cirrhosis (ALC). gMDSCs were defined as the CD33⁺ CD11b^high HLA ⁻ DR ⁻ CD14⁻ CD15⁺ population. The gMDSC population (highlighted in red) was calculated as the proportion of myeloid cells (CD33⁺ CD11b^high). SSC‐A, side scatter; FSC‐A, forward scatter; Live/Dead, fixable dead cell stain. B, Wright–Giemsa staining of flow cytometric‐isolated gMDSCs, bar = 10 μm. C, Cumulative data showing circulating gMDSC frequencies in 23 healthy controls and 105 ALD patients. The ALD patient group included 16 alcoholic hepatitis (AH) patients and 89 alcoholic liver cirrhosis (ALC) patients. D, Cumulative data showing circulating gMDSC frequencies analysed by Child‐Pugh score in patients with ALC. The Child‐Pugh A, B and C groups included 16, 33 and 40 patients, respectively. P‐values are shown